News Posts List
Nonprofit initiates new fund to assist Medicare patients with kidney cancer
01/01/2016
HealthWell fund will provide financial assistance to under-insured patients with renal cell carcinoma.
An Ethical Lapse?
12/20/2015
To this day, there is no evidence that the Coalition has any proper third-party auditing of its funding practices, despite repeated requests.
Linking Cancer and Polycystic Kidney Disease
12/15/2015
Polycystic kidney disease (PKD) is one of the most common inherited diseases—a parent with PKD has a 50 percent chance of passing the disease on to their child.
FDA approves nivolumab for mRCC
12/05/2015
The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy.
Finding Out You Have Kidney Cancer
12/04/2015
Michael Lawing, now 67, wasn't much for going to the doctor. Born and raised in Spindale, North Carolina, he always felt so healthy that he didn't see a need.
Thanks for making #GivingTuesday a success!
12/02/2015
#GivingTuesday raised a total of $2,620 for kidney cancer research, education, and advocacy. Thanks to all who contributed!
Kidney Cancer Might Be Linked To How You Cook Your Meat
11/12/2015
Some potentially good news for all you carnivores out there: A new study shows meat itself might not cause cancer. It could be how you cook it.
Cancer Genetics Reports Biomarker Findings in Metastatic Clear Cell Renal Carcinoma
11/08/2015
Presentation of results from a University of Utah (Huntsman Cancer Institute)-led research study at the 14th International Kidney Cancer Symposium in Miami, Florida, on November 7th, 2015.
Rexahn Pharmaceuticals Reports Interim Clinical Data for Archexin® at the 14th International Kidney Cancer Symposium
11/06/2015
“We are excited to present interim data from the ongoing Phase IIa clinical trial showing that Archexin, in combination with everolimus (Afinitor®), appears to be safe and well tolerated at the doses tested to date.
Initiation Of Phase III First-Line Trial Of Avelumab
11/05/2015
The clinical development program for avelumab now includes more than 1,400 patients who have been treated across more than 15 tumor types, including breast cancer, gastric/gastro-esophageal (GEJ) cancers, head and neck cancer, Merkel cell carcinoma, melanoma, NSCLC, ovarian cancer, renal cell carcinoma and urothelial (e.g., bladder) cancer.